Salvage treatment with intermediate-dose methotrexate and 5-fluorouracil in metastatic breast cancer

S. M. Swain, S. Steinberg, M. Lippman

Research output: Contribution to journalArticle

Abstract

Twenty-six patients (25 evaluable for response) with previously treated metastatic breast cancer were treated with intermediate-dose methotrexate (300 mg/m2) followed by 5-fluorouracil (600 mg/m2) and folinic acid-SF (Leucovorin) rescue (10 mg/m2 q 6 h x 6 doses) with or without tamoxifen (20 mg) and conjugated estrogen (Premarin) (.625 mg twice daily) depending on receptor status. There were two partial responses (8%) with no difference in response between patients who did or did not receive hormones. Toxicity was primarily hematological and elevation of liver function tests. The above schedule has minimal activity in previously treated metastatic breast-cancer patients.

Original languageEnglish (US)
Pages (from-to)445-447
Number of pages3
JournalAmerican Journal of Clinical Oncology: Cancer Clinical Trials
Volume11
Issue number4
DOIs
StatePublished - Jan 1 1988

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Salvage treatment with intermediate-dose methotrexate and 5-fluorouracil in metastatic breast cancer'. Together they form a unique fingerprint.

  • Cite this